newsfilter
← Latest News
GlobeNewswire·

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global